{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:51Z","timestamp":1787166831247,"version":"build-2736575974"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":97,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Qingdao Shengbang Pharmaceutical Corporation Limited, Shandong, China"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Rheum Dis"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1111\/1756-185x.12648","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T12:37:51Z","timestamp":1432730271000},"page":"669-678","source":"Crossref","is-referenced-by-count":43,"title":["A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia"],"prefix":"10.1111","volume":"18","author":[{"given":"Shaoyong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Endocrinology; Xijing Hospital; Fourth Military Medical University; Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Xijing Hospital; Fourth Military Medical University; Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ming","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Xijing Hospital; Fourth Military Medical University; Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenren","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; the Second Affiliated Hospital of Shantou University Medical College; Shantou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; the Affiliated Hospital of Qingdao University; Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; the First Hospital of Shanxi Medical University; Taiyuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; the First Affiliated Hospital of Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongde","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Shanghai General Hospital; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Lanzhou University Second Hospital; Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology; the People's Hospital of Guangxi Zhuang Autonomous Region; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine and Rheumatology; Shaanxi Provincial People's Hospital; Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hand and Foot Surgery; the First Hospital of Jilin University; Jilin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Zhejiang Provincial Tongde Hospital; Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Luoyang Orthopedic-Traumatological Hospital; Luoyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhe","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; Xijing Hospital; Fourth Military Medical University; Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,27]]},"reference":[{"key":"10.1111\/1756-185X.12648-BIB0001|apl12648-cit-0001","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice. Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.12648-BIB0002|apl12648-cit-0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3810\/psm.2011.11.1946","article-title":"2011 recommendations for the diagnosis and management of gout and hyperuricemia","volume":"39","author":"Hamburger","year":"2011","journal-title":"Phys Sportsmed"},{"key":"10.1111\/1756-185X.12648-BIB0003|apl12648-cit-0003","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12648-BIB0004|apl12648-cit-0004","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12648-BIB0005|apl12648-cit-0005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12648-BIB0006|apl12648-cit-0006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/1756-185X.12648-BIB0007|apl12648-cit-0007","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1111\/1756-185X.12648-BIB0008|apl12648-cit-0008","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","article-title":"Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects","volume":"45","author":"Khosravan","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/1756-185X.12648-BIB0009|apl12648-cit-0009","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"10.1111\/1756-185X.12648-BIB0010|apl12648-cit-0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1592\/phco.30.6.594","article-title":"Urate-lowering therapy for gout: focus on febuxostat","volume":"30","author":"Love","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1111\/1756-185X.12648-BIB0011|apl12648-cit-0011","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.12648-BIB0012|apl12648-cit-0012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semarthrit.2013.05.004","article-title":"A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout","volume":"43","author":"Faruque","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/1756-185X.12648-BIB0013|apl12648-cit-0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2318-12-11","article-title":"The efficacy and safety of febuxostat for urate lowering in gout patients >\/=65\u00a0years of age","volume":"12","author":"Jackson","year":"2012","journal-title":"BMC Geriatr"},{"key":"10.1111\/1756-185X.12648-BIB0014|apl12648-cit-0014","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1111\/1756-185X.12648-BIB0015|apl12648-cit-0015","first-page":"CD008653","article-title":"Febuxostat for treating chronic gout","author":"Tayar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/1756-185X.12648-BIB0016|apl12648-cit-0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2474-13-15","article-title":"African American patients with gout: efficacy and safety of febuxostat vs allopurinol","volume":"13","author":"Wells","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1111\/1756-185X.12648-BIB0017|apl12648-cit-0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0091270010365549","article-title":"Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects","volume":"51","author":"Grabowski","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/1756-185X.12648-BIB0018|apl12648-cit-0018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1759720X11416405","article-title":"Efficacy and safety of febuxostat in patients with hyperuricemia and gout","volume":"3","author":"Garcia-Valladares","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1111\/1756-185X.12648-BIB0019|apl12648-cit-0019","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/1756-185X.12648-BIB0020|apl12648-cit-0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12648-BIB0021|apl12648-cit-0021","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/1756-185X.12648-BIB0022|apl12648-cit-0022","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","article-title":"An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia","volume":"17","author":"Huang","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1111\/1756-185X.12648-BIB0023|apl12648-cit-0023","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clinthera.2012.12.011","article-title":"Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis","volume":"35","author":"Ye","year":"2013","journal-title":"Clin Ther"},{"key":"10.1111\/1756-185X.12648-BIB0024|apl12648-cit-0024","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","article-title":"An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study","volume":"17","author":"Kamatani","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/1756-185X.12648-BIB0025|apl12648-cit-0025","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/RHU.0b013e31821d352f","article-title":"An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study","volume":"17","author":"Naoyuki","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1111\/1756-185X.12648-BIB0026|apl12648-cit-0026","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/RHU.0b013e31821d351d","article-title":"Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study","volume":"17","author":"Naoyuki","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/1756-185X.12648-BIB0027|apl12648-cit-0027","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12648","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/1756-185X.12648\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T10:55:03Z","timestamp":1625482503000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,27]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12648","relation":{},"ISSN":["1756-1841"],"issn-type":[{"value":"1756-1841","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,27]]}}}